11,219 Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by Sowell Financial Services LLC

Sowell Financial Services LLC lifted its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 501.1% during the third quarter, Holdings Channel reports. The institutional investor owned 13,458 shares of the specialty pharmaceutical company’s stock after buying an additional 11,219 shares during the quarter. Sowell Financial Services LLC’s holdings in Jazz Pharmaceuticals were worth $3,116,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. USA Financial Formulas acquired a new stake in Jazz Pharmaceuticals in the first quarter valued at approximately $25,000. Pension & Wealth Management Advisors Inc. purchased a new position in Jazz Pharmaceuticals in the third quarter worth $32,000. Ameritas Advisory Services LLC purchased a new position in Jazz Pharmaceuticals in the second quarter worth $47,000. Westpac Banking Corp acquired a new position in shares of Jazz Pharmaceuticals during the first quarter worth $51,000. Finally, Root Financial Partners LLC increased its position in shares of Jazz Pharmaceuticals by 42.8% during the first quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock worth $56,000 after purchasing an additional 89 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Down 0.8%

JAZZ stock opened at $211.97 on Thursday. The stock has a market capitalization of $13.76 billion, a PE ratio of 14.62, a price-to-earnings-growth ratio of 0.22 and a beta of 0.37. Jazz Pharmaceuticals PLC has a 52 week low of $128.80 and a 52 week high of $266.38. The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. The firm has a 50 day moving average of $237.36 and a 200 day moving average of $232.77.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.11 billion. During the same quarter in the previous year, the company posted ($8.25) EPS. The company’s revenue for the quarter was up 15.5% compared to the same quarter last year. Sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 21.59 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on JAZZ shares. Citigroup assumed coverage on Jazz Pharmaceuticals in a report on Wednesday, September 30th. They set a “buy” rating and a $325.00 price objective for the company. Weiss Ratings upgraded Jazz Pharmaceuticals from a “hold (c-)” rating to a “buy (b-)” rating in a research note on Tuesday, August 4th. Truist Financial boosted their target price on Jazz Pharmaceuticals from $281.00 to $286.00 and gave the stock a “buy” rating in a research note on Wednesday, October 7th. Robert W. Baird upped their target price on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the company a “buy” rating in a research note on Wednesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $290.85.

Insider Activity at Jazz Pharmaceuticals

In other news, CEO Renée Galá sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $236.40, for a total transaction of $472,800.00. Following the completion of the sale, the chief executive officer directly owned 141,394 shares in the company, valued at approximately $33,425,541.60. The trade was a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena Patil sold 1,200 shares of the business’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $240.94, for a total transaction of $289,128.00. Following the sale, the executive vice president directly owned 47,671 shares in the company, valued at $11,485,850.74. This trade represents a 2.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 100,121 shares of company stock valued at $24,855,802. 4.10% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.